AC Immune (ACIU) Current Deferred Revenue (2014 - 2025)

AC Immune (ACIU) has 12 years of Current Deferred Revenue data on file, last reported at $104.7 million in Q4 2025.

• Quarterly Current Deferred Revenue rose 7.87% year-over-year to $104.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $104.7 million (up 7.87% YoY) and the FY2025 annual result came in at $101.0 million, up 3.98% from the prior year.
• Current Deferred Revenue improved to $104.7 million in Q4 2025 per ACIU's latest filing, from $97.1 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $777.6 million in Q4 2021 and bottomed at $18467.3 in Q3 2024.
• The 5-year median for Current Deferred Revenue is $542579.3 (2022), against an average of $135.0 million.
• The widest annual swing landed in 2021, when Current Deferred Revenue surged 229626.92%; it then slumped 99.96% in 2022.
• Tracing ACIU's Current Deferred Revenue over 5 years: stood at $777.6 million in 2021, then tumbled by 99.92% to $609318.9 in 2022, then surged by 25432.59% to $155.6 million in 2023, then tumbled by 37.59% to $97.1 million in 2024, then gained by 7.87% to $104.7 million in 2025.
• Per Business Quant, the three latest ACIU Current Deferred Revenue figures stand at $104.7 million (Q4 2025), $97.1 million (Q4 2024), and $18467.3 (Q3 2024).

Peer Comparison